Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 13/20 | 1.00 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | RPA1 | P27694 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116301 | 0.90 | MARS1 (1.00) | MARS1PPP1CAL3MBTL1RPA1SMN1; SMN2 | |
| SCHEMBL1110926 | 0.86 | MARS1 (0.76) | MARS1PPP1CAL3MBTL1RPA1SMN1; SMN2 | |
| SCHEMBL118666 | 0.84 | MARS1 (1.00) | MARS1PPP1CAL3MBTL1RPA1SMN1; SMN2 | |
| SCHEMBL1514559 | 0.84 | PPP1CA (1.00) | MARS1PPP1CAL3MBTL1RPA1SMN1; SMN2 | |
| SCHEMBL117471 | 0.82 | MARS1 (1.00) | MARS1RPA1SMN1; SMN2 | |
| SCHEMBL1110855 | 0.80 | PPP1CA (0.87) | MARS1PPP1CAL3MBTL1RPA1SMN1; SMN2 | |
| SCHEMBL117493 | 0.80 | MARS1 (1.00) | MARS1PPP1CAL3MBTL1RPA1SMN1; SMN2 | |
| SCHEMBL4500796 | 0.78 | L3MBTL1 (1.00) | MARS1PPP1CAL3MBTL1RPA1SMN1; SMN2 | |
| SCHEMBL117374 | 0.78 | MARS1 (1.00) | MARS1L3MBTL1RPA1 | |
| SCHEMBL3684306 | 0.78 | PPP1CA (0.83) | MARS1PPP1CAL3MBTL1RPA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | MARS1 55/4885PPP1CA 2582/4885L3MBTL1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.